Drug Trial Radar · NCT07937696
A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Apr 27, 2027
Primary completion
Nov 30, 2031
Study completion Jul 31, 2032
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well a vaccine called Nous-209 works in reducing the size of abnormal area of tissue growth or polyps (colorectal lesions) in patients with Lynch syndrome. When patients have Lynch syndrome, errors in the genetic information inside cells are not properly corrected. When that happens, the cells produce new proteins called neoantigens. Nous-209 is a vaccine with man-made copies of neoantigens combined with viral vectors. Neoantigens are new proteins that form inside tumor cells when certain mutations occur inside them. The body's immune system recognizes these proteins as foreign and generates a response against the tumor cell that produced the neoantigen. Giving the Nous-209 vaccine may be able to reduce the size of existing colorectal lesions (polyps) that were 5 to 15 mm in diameter at the time of patients' first colonoscopy or flexible sigmoidoscopy.
Conditions
- Colorectal Carcinoma
- EPCAM Lynch Syndrome
- Lynch Syndrome
- MLH1 Lynch Syndrome
- MSH2 Lynch Syndrome
- MSH6 Lynch Syndrome
- PMS2 Lynch Syndrome
Interventions
Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSPBiological
Given IM
Biopsy ProcedureProcedure
Undergo tissue biopsies
Biospecimen CollectionProcedure
Undergo blood sample collection
ColonoscopyProcedure
Undergo colonoscopy
MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSPBiological
Given IM
SigmoidoscopyProcedure
Undergo flexible sigmoidoscopy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participant-level response rateTime frame: Baseline to week 16
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of Kansas Cancer Center
Kansas City, Kansas
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan
Fox Chase Cancer Center
Philadelphia, Pennsylvania
UT MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.